Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?

Julia M Hofstra; Jack F M Wetzels

doi:10.1016/j.kint.2016.01.019

Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?

Kidney Int. 2016 May;89(5):981-983. doi: 10.1016/j.kint.2016.01.019.

Authors

Julia M Hofstra¹, Jack F M Wetzels²

Affiliations

¹ Radboud University Medical Centre, Department of Nephrology, Nijmegen, the Netherlands.
² Radboud University Medical Centre, Department of Nephrology, Nijmegen, the Netherlands. Electronic address: [email protected].

PMID: 27083274
DOI: 10.1016/j.kint.2016.01.019

Abstract

Patients with nephrotic syndrome are at increased risk of thrombosis. The risk of venous thrombosis is particularly high in patients with nephrotic syndrome due to primary membranous nephropathy. Recent data provide evidence that these patients also have a high absolute risk of arterial thrombotic events, which is associated with the degree of hypoalbuminemia. In this commentary we discuss whether prophylactic aspirin therapy might be indicated in this patient population.

Publication types

Comment

MeSH terms

Anticoagulants
Aspirin*
Glomerulonephritis, Membranous / drug therapy*
Humans
Nephrotic Syndrome
Primary Prevention
Thrombosis

Substances

Anticoagulants
Aspirin